AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
NextCure, Inc.
Video analysis: NXTC
All videosNo video analysis for this stock yet. Request one from our team.
News: NXTC
NextCure (NASDAQ:NXTC) Stock Price Up 7.7% – Time to Buy?
NextCure, Inc. (NASDAQ: NXTC - Get Free Report)'s stock price was up 7.7% during trading on Tuesday. The company traded as high as $8.64 and last traded at $8.42. 95,035 shares were traded during mid-day trading, a decline of 36% from the average daily volume of 147,812 shares. The stock had previously closed at $7.82.
Avere Therapeutics Announces $500 Million Private Placement to Support Development of Once-Weekly Oral IL-23 Therapy AVR-001
Additional financing from a world-class investor syndicate further strengthens the combined company's balance sheet to accelerate development of AVR-001 Private placement and the previously announced concurrent private placement are expected to fully fund Avere's operating plan into 2029 SAN FRANCISCO, Aug. 10, 2026 /PRNewswire/ -- Avere Therapeutics, Inc. ("Avere" or the "Company"), a privately-held biotechnology company advancing oral therapies for IL-23 driven inflammatory diseases, today announced a $500 million private placement (the "Private Placement") from a syndicate of leading healthcare investors. The Private Placement is in addition to the previously announced $320 million concurrent private investment, and the combined proceeds will support the continued development of Avere's lead program, AVR-001, a once-weekly oral IL-23 receptor antagonist.
NextCure, Inc. (NASDAQ:NXTC) Sees Large Increase in Short Interest
NextCure, Inc. (NASDAQ: NXTC - Get Free Report) was the target of a large increase in short interest in the month of July. As of July 15th, there was short interest totaling 1,323,834 shares, an increase of 734.7% from the June 30th total of 158,592 shares. Approximately 41.6% of the shares of the stock are short
Halper Sadeh LLC is Investigating Whether VEEE, NXTC, TCBK, FHB are Obtaining Fair Deals for their Shareholders
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
The M&A Class Action Firm Encourages $hareholders To Contact Monteverde Concerning The Merger—VEEE, NXTC, TCBK, and FHB
NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating
$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger--VEEE, NXTC, TCBK, and FHB
$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger--VEEE, NXTC, TCBK, and FHB PR Newswire
Are CRNX, VEEE, NXTC, TCBK Obtaining Fair Deals for their Shareholders?
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger—VEEE, NXTC, TCBX, and FHB
NEW YORK, July 21, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating
